The Theranos scandal was a years-long securities fraud in which founder Elizabeth Holmes and company president Ramesh “Sunny” Balwani raised more than $700 million from investors by lying about a blood-testing technology that did not work as advertised, producing unreliable results for real patients before whistleblowers, regulators, and federal prosecutors brought the company down. Both executives were convicted of wire fraud, sentenced to more than a decade each in federal prison, and ordered to pay $452 million in restitution.1United States Department of Justice. U.S. v. Elizabeth Holmes, et al. The company dissolved in 2018.
The Promise That Did Not Match the Machine
Holmes founded Theranos in 2003 after dropping out of Stanford at 19. The pitch was straightforward: a proprietary analyzer called the Edison, paired with a small blood-collection tube called the Nanotainer, could run more than 200 diagnostic tests from a few drops of finger-stick blood. Cheaper, faster, less painful than a traditional venous draw.
The reality inside the lab looked nothing like the pitch. The Edison handled only about 12 to 15 of those tests. The rest were run on commercial analyzers made by Siemens and other manufacturers that any hospital lab would have recognized. Because finger-stick samples were too small for machines designed to process a full venous draw, technicians diluted them to reach the required volume. Running diluted blood through equipment calibrated for undiluted blood produced unreliable results. Staff sometimes ran multiple measurements and averaged them, discarding outliers. One comparative study of 60 healthy adults found the odds of Theranos missing a measurement due to technical error were 12.5 to 1 compared to established labs like LabCorp and Quest Diagnostics.
Theranos eventually voided two years’ worth of Edison test results and issued tens of thousands of corrected reports to doctors and patients. Some of those patients had already made medical decisions based on numbers that were wrong.
What Holmes and Balwani Told Investors
Theranos raised more than $700 million at a peak valuation of roughly $9 billion, briefly making Holmes the youngest self-made female billionaire in the country on paper. The money came largely from wealthy individuals and family offices rather than venture capital firms with healthcare expertise. A board stacked with former cabinet officials and senators, including George Shultz, Henry Kissinger, William Perry, Sam Nunn, and Bill Frist, substituted for the technical due diligence experienced biotech investors would have demanded. Most of those board members had no background in laboratory science or medical device regulation.
The financial representations made to those investors were fabricated. Holmes and Balwani told investors the company would generate more than $100 million in revenue in 2014 and roughly $1 billion in 2015. Actual 2014 revenue was a little more than $100,000. Holmes also told investors that Theranos technology was being used by the U.S. Department of Defense on battlefields in Afghanistan and on medevac helicopters. It was not.
In 2013, Theranos signed a commercial deal with Walgreens to open “Wellness Centers” inside retail pharmacies, starting in Arizona. Walgreens’s own scientific advisors raised concerns about the absence of published, peer-reviewed data, but executives overrode them for fear of losing the deal to a competitor. The partnership put unvalidated technology in front of paying patients. After the fraud became public, Walgreens sued Theranos and ultimately paid $44 million into a settlement fund for affected patients.
Regulators Shut the Lab Down
The Centers for Medicare and Medicaid Services inspected the Theranos clinical laboratory in Newark, California, and found serious violations of federal lab standards. CMS determined that failures in hematology testing posed an immediate threat to patient safety. The agency imposed a limitation on the lab’s federal certification, a civil penalty of $10,000 per day for ongoing noncompliance, suspension of Medicare payment approval, and ultimately full revocation of the laboratory’s CLIA certificate effective September 2016. A two-year ban prohibited the lab’s owners and operators, including Holmes personally, from owning, operating, or directing any clinical laboratory.
The company had no other business. Shutting the lab shut Theranos.
How the Fraud Came Out
The unraveling started inside the company. Erika Cheung and Tyler Shultz, both young employees in the Theranos clinical laboratory, independently identified quality-control failures and documented them. Tyler Shultz was the grandson of board member George Shultz, which made his decision to go to regulators a particularly fraught one. Both whistleblowers also brought their concerns to John Carreyrou, an investigative reporter at the Wall Street Journal.
In October 2015, the Journal published a front-page investigation revealing that Theranos was not using its own Edison technology for the vast majority of tests it sold to consumers. The story triggered a cascade of regulatory and criminal investigations. Theranos tried to push back legally, retaining attorney David Boies, whose firm sent threatening letters to former employees and journalists. The reporting held.
The SEC Case
In March 2018, the Securities and Exchange Commission charged Theranos, Holmes, and Balwani with “an elaborate, years-long fraud in which they exaggerated or made false statements about the company’s technology, business, and financial performance.”2Securities and Exchange Commission. Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud The complaint identified the fabricated Department of Defense claims and the inflated revenue projections as central to the deception.3Securities and Exchange Commission. SEC Complaint Against Elizabeth Holmes and Theranos Inc
Holmes settled the civil charges without admitting or denying the allegations. The settlement required her to pay a $500,000 fine, return approximately 18.9 million shares of Theranos stock, and accept a ten-year ban on serving as an officer or director of any public company.4Securities and Exchange Commission. Final Judgment As To Defendant Elizabeth Anne Holmes Balwani did not settle. Theranos itself formally dissolved later that year.
The Criminal Convictions
Federal prosecutors in the Northern District of California charged both executives with wire fraud and conspiracy to commit wire fraud. The two were tried separately. In January 2022, a jury found Holmes guilty on four counts: one count of conspiracy to defraud investors and three counts of wire fraud involving investor transfers totaling more than $140 million. She was acquitted on all charges related to defrauding patients.1United States Department of Justice. U.S. v. Elizabeth Holmes, et al.
Balwani’s trial produced a harsher result. The jury convicted him on all twelve felony counts, including the patient-fraud charges Holmes beat. The split likely reflected his direct role in day-to-day laboratory operations where the patient-facing deception happened.
Holmes received a sentence of eleven years and three months in federal prison. Balwani received twelve years and ten months. Both were ordered to pay $452 million in restitution to fraud victims. The restitution figure dwarfs either defendant’s ability to pay. While incarcerated, Holmes was paying $25 every three months toward the balance; federal prosecutors have sought an order requiring at least $250 per month or ten percent of her earnings after release.
Where Things Stand Now
Holmes appealed to the Ninth Circuit Court of Appeals. In February 2025, the court affirmed her conviction, her sentence, and the $452 million restitution order in full.5United States Courts for the Ninth Circuit. United States v. Elizabeth Holmes That was her last realistic chance to overturn the verdict.
Holmes is serving her sentence at a federal prison camp in Bryan, Texas. Good-conduct credits have twice reduced her time, bringing her projected release to August 2032. Balwani was released on furlough to the Santa Barbara area in January 2026, with a projected full release date of April 2033. The $452 million restitution obligation will follow both of them long after they leave prison, and victims are unlikely to ever be fully repaid.